Goldman Sachs’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Goldman Sachs’s Portfolio RVPH Stock Details RVPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-612	Closed	-$51.3K	–	6032
2023 Q1	$51.3K	Sell	612 -849	-58%	-$74.1K	﹤0.01%	5548
2022 Q4	$124K	Buy	+1,461	New	+$111K	﹤0.01%	5431
2020 Q4	–	Sell	-7,500	Closed	-$1.62M	–	5680
2020 Q3	$1.62M	Hold	7,500	–	–	﹤0.01%	3716
2020 Q2	$1.61M	Hold	7,500	–	–	﹤0.01%	3605
2020 Q1	$1.58M	Hold	7,500	–	–	﹤0.01%	3463
2019 Q4	$1.57M	Hold	7,500	–	–	﹤0.01%	3814
2019 Q3	$1.55M	Hold	7,500	–	–	﹤0.01%	3716
2019 Q2	$1.53M	Hold	7,500	–	–	﹤0.01%	3699
2019 Q1	$1.51M	Hold	7,500	–	–	﹤0.01%	3807
2018 Q4	$1.47M	Buy	+7,500	New	+$1.47M	﹤0.01%	3729

Other funds holding RVPH

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Goldman Sachs's RVPH Position: Q2 2023 in Review

Goldman Sachs sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2023, closing a stake of 612 shares — an estimated $51.3K sold.

Goldman Sachs first reported a position in RVPH in Q4 2018 and held it in 10 quarters. The position peaked at $1.62M in Q3 2020. 23 funds tracked by Wall St. Rank hold RVPH as of Q2 2023.

Goldman Sachs reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2023 after selling out during the quarter.
Goldman Sachs sold 612 REVIVA PHARMA HLDGS INC shares in Q2 2023, an estimated $51.3K.
Goldman Sachs first reported a position in REVIVA PHARMA HLDGS INC in Q4 2018 and held it in 10 quarters.
Goldman Sachs's REVIVA PHARMA HLDGS INC position peaked at $1.62M in Q3 2020.
23 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.